Aplicación farmacogenómica de los genes CYP2C19, CYP2C9 y VKORC1 implicados en el metabolismo de los fármacos clopidogrel y warfarina

Vélez Gómez, Sara; Torres, Isaura; Manrique, Ruben Dario; Duque, Mauricio; Gallo, Juan Esteban.
Rev. colomb. cardiol ; 25(6): 396-404, nov.-dic. 2018. tab, graf
Artículo en Español | LILACS, COLNAL | ID: biblio-1058367

Documentos relacionados

  1. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
  2. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
  3. Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents.
  4. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
  5. Electrochemical peptide nucleic acid functionalized &#945;-Fe<sub>2</sub>O<sub>3</sub>/Fe<sub>3</sub>O<sub>4</sub> nanosheets for detection of CYP2C19*2 gene.
  6. Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians.
  7. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
  8. Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping.
  9. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
  10. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.